Ambica International Corporation Promeddazole Metronidazole Philippines - English - FDA (Food And Drug Administration)

ambica international corporation promeddazole metronidazole

akums drugs & pharmaceuticals ltd. (plant iii-injectables) - drug - metronidazole - promeddazole

SUNITINIB TARO 12.5 MG Israel - English - Ministry of Health

sunitinib taro 12.5 mg

taro international ltd, israel - sunitinib - hard capsule - sunitinib 12.5 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TARO 25 MG Israel - English - Ministry of Health

sunitinib taro 25 mg

taro international ltd, israel - sunitinib - hard capsule - sunitinib 25 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TARO 37.5 MG Israel - English - Ministry of Health

sunitinib taro 37.5 mg

taro international ltd, israel - sunitinib - hard capsule - sunitinib 37.5 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TARO 50 MG Israel - English - Ministry of Health

sunitinib taro 50 mg

taro international ltd, israel - sunitinib - hard capsule - sunitinib 50 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TEVA 12.5 MG Israel - English - Ministry of Health

sunitinib teva 12.5 mg

teva israel ltd - sunitinib as base - capsules - sunitinib as base 12.5 mg - sunitinib - sunitinib teva is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib teva is indicated for the treatment of advanced renal cell carcinoma. treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TEVA 25 MG Israel - English - Ministry of Health

sunitinib teva 25 mg

teva israel ltd - sunitinib as base - capsules - sunitinib as base 25 mg - sunitinib - sunitinib teva is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib teva is indicated for the treatment of advanced renal cell carcinoma. treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TEVA 37.5 MG Israel - English - Ministry of Health

sunitinib teva 37.5 mg

teva israel ltd - sunitinib as base - capsules - sunitinib as base 37.5 mg - sunitinib - sunitinib teva is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib teva is indicated for the treatment of advanced renal cell carcinoma. treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TEVA 50 MG Israel - English - Ministry of Health

sunitinib teva 50 mg

teva israel ltd - sunitinib as base - capsules - sunitinib as base 50 mg - sunitinib - sunitinib teva is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib teva is indicated for the treatment of advanced renal cell carcinoma. treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB MSN sunitinib (as malate) 37.5 mg hard capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

sunitinib msn sunitinib (as malate) 37.5 mg hard capsule bottle

accelagen pty ltd - sunitinib malate, quantity: 50.118 mg (equivalent: sunitinib, qty 37.5 mg) - capsule, hard - excipient ingredients: croscarmellose sodium; mannitol; gelatin; pregelatinised maize starch; titanium dioxide; magnesium stearate; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; purified water; shellac; strong ammonia solution; potassium hydroxide; iron oxide black - sunitinib msn is indicated for;,treatment of advanced renal cell carcinoma (rcc),treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net)